Aktis Oncology (NASDAQ:AKTS) Stock Price Up 7.2% – Here’s What Happened

Aktis Oncology (NASDAQ:AKTS)’s stock price was up 7.2% on Monday . The company traded as high as $20.59 and last traded at $20.3630. Approximately 226,889 shares were traded during mid-day trading, a decline of 13% from the average daily volume of 260,851 shares. The stock had previously closed at $18.99.

Analysts Set New Price Targets

AKTS has been the topic of a number of research reports. Wall Street Zen raised shares of Aktis Oncology to a “hold” rating in a research report on Saturday, January 17th. HC Wainwright started coverage on shares of Aktis Oncology in a research note on Monday, March 9th. They set a “buy” rating and a $30.00 price objective on the stock. JPMorgan Chase & Co. assumed coverage on shares of Aktis Oncology in a report on Tuesday, February 3rd. They set an “overweight” rating and a $30.00 price objective on the stock. TD Cowen started coverage on shares of Aktis Oncology in a research note on Tuesday, February 3rd. They issued a “buy” rating for the company. Finally, Bank of America assumed coverage on Aktis Oncology in a research report on Tuesday, February 3rd. They set a “buy” rating and a $34.00 target price on the stock. Five investment analysts have rated the stock with a Buy rating, According to MarketBeat.com, Aktis Oncology currently has an average rating of “Buy” and a consensus price target of $31.25.

Aktis Oncology Trading Up 4.6%

The firm’s fifty day moving average price is $19.71.

Insiders Place Their Bets

In other Aktis Oncology news, major shareholder Vida Ventures Ii, Llc acquired 835,000 shares of the stock in a transaction dated Monday, January 12th. The stock was purchased at an average price of $18.00 per share, with a total value of $15,030,000.00. Following the transaction, the insider directly owned 5,671,825 shares of the company’s stock, valued at $102,092,850. This trade represents a 17.26% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, major shareholder Bioventures 2018 L.P. Mpm bought 1,112,777 shares of Aktis Oncology stock in a transaction that occurred on Monday, January 12th. The shares were acquired at an average cost of $18.00 per share, for a total transaction of $20,029,986.00. Following the completion of the transaction, the insider directly owned 10,260,064 shares in the company, valued at $184,681,152. This represents a 12.17% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last ninety days, insiders bought 6,117,776 shares of company stock valued at $110,119,968.

About Aktis Oncology

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.